Metabolic Reprogramming Consequences of Sepsis: Adaptations and Contradictions
Overview
Affiliations
During sepsis, the importance of alterations in cell metabolism is underappreciated. The cellular metabolism, which has a variable metabolic profile in different cells and disease stages, is largely responsible for the immune imbalance and organ failure associated with sepsis. Metabolic reprogramming, in which glycolysis replaces OXPHOS as the main energy-producing pathway, is both a requirement for immune cell activation and a cause of immunosuppression. Meanwhile, the metabolites produced by OXPHOS and glycolysis can act as signaling molecules to control the immune response during sepsis. Sepsis-induced "energy shortage" leads to stagnated cell function and even organ dysfunction. Metabolic reprogramming can alleviate the energy crisis to some extent, enhance host tolerance to maintain cell survival functions, and ultimately increase the adaptation of cells during sepsis. However, a switch from glycolysis to OXPHOS is essential for restoring cell function. This review summarized the crosstalk between metabolic reprogramming and immune cell activity as well as organ function during sepsis, discussed the benefits and drawbacks of metabolic reprogramming to show the contradictions of metabolic reprogramming during sepsis, and assessed the feasibility of treating sepsis through targeted metabolism. Using metabolic reprogramming to achieve metabolic homeostasis could be a viable therapy option for sepsis.
Russkikh I, Popov O, Klochkova T, Sushentseva N, Apalko S, Asinovskaya A Sci Rep. 2025; 15(1):6622.
PMID: 39994234 PMC: 11850835. DOI: 10.1038/s41598-025-90426-0.
System-based insights into parasitological and clinical treatment failure in Chagas disease.
Ernst L, Macedo G, McCall L mSystems. 2025; 10(2):e0003824.
PMID: 39772644 PMC: 11834445. DOI: 10.1128/msystems.00038-24.
The impact of glucose metabolism on inflammatory processes in sepsis-induced acute lung injury.
Cheng S, Li Y, Sun X, Liu Z, Guo L, Wu J Front Immunol. 2024; 15:1508985.
PMID: 39712019 PMC: 11659153. DOI: 10.3389/fimmu.2024.1508985.
Liu A, Tan B, Yang P, Tian N, Li J, Wang S Front Immunol. 2024; 15:1487576.
PMID: 39544947 PMC: 11560457. DOI: 10.3389/fimmu.2024.1487576.
Novel coenzyme Q6 genetic variant increases susceptibility to pneumococcal disease.
Walker E, Javati S, Todd E, Matlam J, Lin X, Bryant M Nat Immunol. 2024; 25(12):2247-2258.
PMID: 39496954 PMC: 11908386. DOI: 10.1038/s41590-024-01998-4.